Data / Form D filings / Ansa Biotechnologies, Inc.
Ansa Biotechnologies, Inc.: Form D filings
Ansa Biotechnologies, Inc., a biotechnology company in Emeryville, CA, filed 6 Form D notices with the SEC between 2020 and 2025. The latest, on December 10, 2025, reports $46.4 million sold of a $56.9 million offering to 41 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1198 65TH STREET #250, Emeryville, CA, 94608
- Phone
- (925) 690-8100
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1816722
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 10, 2025 | Amendment | $56,934,922 | $46,449,665 | $10,485,257 | 41 | Jun 28, 2024 | sec.gov |
| Oct 2, 2025 | New notice | $55,477,037 | $45,199,665 | $10,277,372 | 39 | Jun 28, 2024 | sec.gov |
| May 5, 2022 | Amendment | $76,671,201 | $67,999,951 | $8,671,250 | 28 | Mar 18, 2022 | sec.gov |
| Apr 14, 2022 | New notice | $76,671,201 | $67,724,967 | $8,946,234 | 23 | Mar 18, 2022 | sec.gov |
| Oct 15, 2021 | New notice | $5,000,000 | $5,000,000 | 7 | Oct 8, 2021 | sec.gov | |
| Jul 9, 2020 | New notice | $9,213,151 | $4,734,242 | $4,478,909 | 24 | Jun 24, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jason T. Gammack | Executive Officer, Director | |
| Yanniv T. Dorone | Director | |
| Daniel T. Lin-Arlow | Executive Officer, Director | |
| Chenny T. Zhang | Director | |
| Matthew T. McManus | Director | |
| Sebastian T. Palluk | Executive Officer |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Dec 8, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Ansa Biotechnologies, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.